Decentralised Clinical Trials in Focus
Overview
The advantages of decentralised clinical trials (DCTs) are generally recognised, especially the opportunity to make clinical trials more patient centric. Additional benefits are increasingly in evidence, such as improved patient recruitment, retention, and enhanced data quality. Nonetheless, there is a way to go before decentralised clinical trials are the standard rather than the optional model. Not surprisingly, technology and operational challenges appear to still be a stumbling block as sponsors get to grips with introducing new ways of working with sites and patients along with timeline demand in trials.
World-Class Business Leaders and Speakers. More to be confirmed.
Financial value in DCTs
What is the underlying evidence for improved financial outcomes from DCTs when compared to conventional trials? How can economic/ financial value in DCTs be measured? Exploring the emerging metrics.
Technology and operational challenges
What are the types of technology and operational challenges sponsors are experiencing – are they teething problems or significant?
Experiences of clinical leaders
What have been the experiences of clinical/ development leaders in the last year? Where have they seen the benefits and value of DCTs emerging? How are they taking account of these in decision making?
Aired on 26 September
FT Live Digital Dialogues - 50 minute experience delivering maximum engagement. Live webinars provide unique opportunities to engage global senior audiences. All access, digital passes include access to all the live sessions PLUS all sessions on demand for 30 days. Join the conversation.
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice